Description
AMG is currently under investigation and has not been approved for use in colorectal cancer. Its clinical efficacy and safety profile are still being evaluated through ongoing clinical trials.
Mechanism of Action
AMG is an investigational drug and its mechanism of action has not been fully elucidated or approved by the FDA for clinical use in colorectal cancer.
Side Effects
Side effects are not yet fully known as AMG is still under investigation; however
Common side effects may include fatigue
Nausea
And hematological abnormalities.
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT06131398
med_phase_prefix1
Active, not recruiting
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
United States, Australia, Canada, France, Japan, Netherlands, Poland, South Kore
NCT02713529
med_phase_prefix1
Archived
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
United States, Australia, Belgium, Canada, Germany, Spain
NCT02437916
med_phase_prefix1
Archived
Safety Study of AMG 228 to Treat Solid Tumors
United States, Australia, Belgium, France, Germany
NCT01562899
med_phase_prefix1
Archived
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
United States, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
NCT00813605
med_phase_prefix2
Archived
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
United States, France, Hong Kong, Hungary, India, Italy, Poland, Russia, Singapo
NCT00819169
med_phase_prefix1
Archived
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors